Nasdaq · Healthcare
ADMA BIOLOGICS, INC. (ADMA)
As-reported financials and recent SEC filings for ADMA BIOLOGICS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$510.2M
Net income
$146.9M
Net margin
28.8%
Diluted EPS
$0.60
ROE
30.8%
P/E (TTM)
12.9×
Market cap
$2.03B
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $510.2M | $426.5M | $258.2M | $154.1M | $80.9M |
| Gross profit | $292.8M | $219.6M | $88.9M | $35.3M | $1.2M |
| Operating income | $191.4M | $139.0M | $21.6M | $-39.4M | $-58.4M |
| Net income | $146.9M | $197.7M | $-28.2M | $-65.9M | $-71.6M |
| Diluted EPS | $0.60 | $0.81 | $-0.13 | $-0.33 | $-0.51 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-02
View on EDGAR →42026-05-28
View on EDGAR →42026-05-14
View on EDGAR →42026-05-12
View on EDGAR →10-Q2026-05-06
View on EDGAR →8-K2026-05-06
View on EDGAR →8-K2026-05-04
View on EDGAR →SCHEDULE 13G2026-04-29
View on EDGAR →Go deeper on ADMA
Search ADMA BIOLOGICS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.